Perceived Impacts and Predictors of Cannabis Products used by Rheumatology Patients in Alberta: A Multivariable Analysis of Cross‐sectional Survey Data

OBJECTIVE: This study aimed to characterize cannabis product choices (cannabinoid content and formulation) among rheumatology patients, and their associations with patient factors, patient reported perceived side effects and positive impacts. METHODS: An online survey (delivered from March to November 2022) was distributed by Alberta Health Services to rheumatology patients in Alberta. Correlation matrices were used to analyzed associations between cannabinoid content and formulations reportedly used with patient factors and patient-reported outcomes. Efficacy outcomes (e.g. pain, sleep, mood) were grouped into a composite positive impact score and side effects were grouped into CNS activating, dampening, and sensory effects. RESULTS: Data from 1,436 respondents who indicated cannabis use and provided information on their rheumatologic condition, cannabinoid content and formulations that they use were analyzed. THC-CBD balanced products were associated with higher positive impact scores, aOR(95%CI)=1.76(1.18-2.63). THC-dominant products were also associated with high dampening and sensory effects, aOR=1.85(1.16-2.98) and 2.16(1.27-3.70), respectively. Dried cannabis and edibles were associated with higher positive impact scores aOR=1.86(1.07-3.23), and 2.18(1.41-3.37), respectively. Dried cannabis was also associated with high dampening and sensory effects, aOR=1.98(1.19-3.27) and 3.05(1.67-5.58) respectively. Cannabis product choice varied by age, gender, comorbidities, prior cannabis experience, frequency of use, reasons for use, access to cannabis prescription and source of cannabis information. CONCLUSION: There is significant variability in cannabis products used by rheumatology patients, which are influenced by patient-specific factors. Balancing THC and CBD content may facilitate positive impact while lowering risk for side effects. Dried cannabis may pose more side effects compared to other formulations.

Authors

Institutions

Publication Details

Journal
Arthritis Care & Research
Published
2026-04-27
DOI
https://doi.org/10.1002/acr.80071
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Perceived Impacts and Predictors of Cannabis Products used by Rheumatology Patients in Alberta: A Multivariable Analysis of Cross‐sectional Survey Data

C Allyson Jones, Linda Kolewaski, Elaine Yacyshyn, Joanne Olson et al.
Arthritis Care & Research
Cannabis and Cannabinoid Research
article

Perceived Impacts and Predictors of Cannabis Products used by Rheumatology Patients in Alberta: A Multivariable Analysis of Cross‐sectional Survey Data

C Allyson Jones, Linda Kolewaski, Elaine Yacyshyn, Joanne Olson, Samuel Lowe, Pauline Paul, Tarek Turk, Susan Zhang, Cheryl A. Sadowski, Shelby Yamamoto, Frank Sun
article en

Abstract

OBJECTIVE: This study aimed to characterize cannabis product choices (cannabinoid content and formulation) among rheumatology patients, and their associations with patient factors, patient reported perceived side effects and positive impacts. METHODS: An online survey (delivered from March to November 2022) was distributed by Alberta Health Services to rheumatology patients in Alberta. Correlation matrices were used to analyzed associations between cannabinoid content and formulations reportedly used with patient factors and patient-reported outcomes. Efficacy outcomes (e.g. pain, sleep, mood) were grouped into a composite positive impact score and side effects were grouped into CNS activating, dampening, and sensory effects. RESULTS: Data from 1,436 respondents who indicated cannabis use and provided information on their rheumatologic condition, cannabinoid content and formulations that they use were analyzed. THC-CBD balanced products were associated with higher positive impact scores, aOR(95%CI)=1.76(1.18-2.63). THC-dominant products were also associated with high dampening and sensory effects, aOR=1.85(1.16-2.98) and 2.16(1.27-3.70), respectively. Dried cannabis and edibles were associated with higher positive impact scores aOR=1.86(1.07-3.23), and 2.18(1.41-3.37), respectively. Dried cannabis was also associated with high dampening and sensory effects, aOR=1.98(1.19-3.27) and 3.05(1.67-5.58) respectively. Cannabis product choice varied by age, gender, comorbidities, prior cannabis experience, frequency of use, reasons for use, access to cannabis prescription and source of cannabis information. CONCLUSION: There is significant variability in cannabis products used by rheumatology patients, which are influenced by patient-specific factors. Balancing THC and CBD content may facilitate positive impact while lowering risk for side effects. Dried cannabis may pose more side effects compared to other formulations.

Arthritis Care & Research
University of Alberta (CA), Canadian Patient Safety Institute (CA)
Gender equality
Openalex Percentile: Top 11%
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.